AACR 2023 | Elraglusib, a novel small molecule inhibitor of GSK-3

Taylor Weiskittel, Mayo Clinic, Rochester, MN, provides an overview of elraglusib, and the rationale behind targeting GSK-3. Elraglusib has shown promising pre-clinical anti-tumor activity and the investigational drug targets GSK-3, which as shown to additionally have a positive effect on the immune system. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.